Zen­tal­is shakes up PhI­II plans in ovar­i­an can­cer; Halozyme's deal with Acu­men; Ko­r­ro's $117M pri­vate place­ment

Zen­tal­is Phar­ma shakes up plans for Phase III in ovar­i­an can­cer: Zen­tal­is an­nounced Mon­day that it is no longer plan­ning to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.